TY - JOUR T1 - Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery JF - Anticancer Research JO - Anticancer Res SP - 2247 LP - 2252 VL - 38 IS - 4 AU - MORGANE PERRIN AU - ENRICA BENTIVEGNA AU - CLAIRE BONNEAU AU - CATHERINE UZAN AU - ALEXANDRA LEARY AU - PATRICIA PAUTIER AU - CATHERINE GENESTIE AU - PHILIPPE MORICE AU - SÉBASTIEN GOUY Y1 - 2018/04/01 UR - http://ar.iiarjournals.org/content/38/4/2247.abstract N2 - Background/Aim: We aimed to evaluate the impact of bevacizumab on the lymphocele rate in patients after complete cytoreductive surgery for advanced ovarian cancer. Patients and Methods: This retrospective study included patients with advanced ovarian cancer who had undergone complete cytoreductive surgery with pelvic and para-aortic lymphadenectomy at the Gustave Roussy Institute from 2005 to 2014. The introduction of bevacizumab was discussed in a multidisciplinary meeting. Results: During the study period, 247 patients were included; 24.6% of patients (61 patients) received adjuvant bevacizumab. The rate of symptomatic lymphocele was 34% (84 patients). In the lymphocele group, patients tended to receive adjuvant bevacizumab more often than did the control group (32% and 21%, respectively, p=0.05). In multivariate analysis, bevacizumab was not significantly associated with the risk of symptomatic lymphocele (hazard ratio(HR)=1.62, 95% confidence interval(CI)=0.87-3.01, p=0.12). Conclusion: Adjuvant bevacizumab has no impact on the formation or duration of symptomatic lymphocele in patients after complete cytoreductive surgery for advanced ovarian cancer. ER -